Literature DB >> 1906877

Molecular characterization of a unique von Willebrand disease variant. A novel mutation affecting von Willebrand factor/factor VIII interaction.

P M Cacheris1, W C Nichols, D Ginsburg.   

Abstract

von Willebrand factor (vWF) plays a central role in blood coagulation, mediating the adhesion of the initial platelet plug to the subendothelium, and serving as the carrier for factor VIII (FVIII) in the circulation. In previous studies, we have mapped the epitope for an anti-vWF monoclonal antibody which inhibits the interaction between FVIII and vWF to a region spanning Thr78 to Thr96 of the mature protein (Bahou, W.F., Ginsburg, D., Sikkink, R., Litwiller, R., and Fass, D. N. (1989) J. Clin. Invest. 84, 56-61). We now report the identification of a mutation within this region of vWF that results in decreased FVIII binding. Sequence analysis of polymerase chain reaction amplified platelet vWF mRNA from a von Willebrand disease (vWD) patient with a disproportionately low FVIII level identified a single nucleotide substitution (G----A), resulting in the conversion of Arg91----Gln. Recombinant vWF carrying this substitution showed decreased binding to FVIII compared with wild-type vWF or vWF carrying a polymorphic substitution in the same region (Arg89----Gln). These observations suggest a critical role for Arg91 in the interaction of vWF with FVIII and identify the molecular mechanism for a variant of vWD associated with unusually low FVIII levels.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1906877

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  A von Willebrand factor fragment containing the D'D3 domains is sufficient to stabilize coagulation factor VIII in mice.

Authors:  Andrew Yee; Robert D Gildersleeve; Shufang Gu; Colin A Kretz; Beth M McGee; Keisha M Carr; Steven W Pipe; David Ginsburg
Journal:  Blood       Date:  2014-05-21       Impact factor: 22.113

2.  Defective dimerization of von Willebrand factor subunits due to a Cys-> Arg mutation in type IID von Willebrand disease.

Authors:  R Schneppenheim; J Brassard; S Krey; U Budde; T J Kunicki; L Holmberg; J Ware; Z M Ruggeri
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-16       Impact factor: 11.205

Review 3.  Von Willebrand's disease.

Authors:  I M Nilsson; S Lethagen
Journal:  Indian J Pediatr       Date:  1993 Mar-Apr       Impact factor: 1.967

4.  Functional analysis of a type IIB von Willebrand disease missense mutation: increased binding of large von Willebrand factor multimers to platelets.

Authors:  K A Cooney; S E Lyons; D Ginsburg
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-01       Impact factor: 11.205

5.  A novel case of compound heterozygosity with "Normandy"/type I von Willebrand disease (vWD). Direct demonstration of the segregation of one allele with a defective expression at the mRNA level causing type I vWD.

Authors:  V Siguret; J M Lavergne; G Chérel; C Boyer-Neumann; A S Ribba; B R Bahnak; D Meyer; G Piétu
Journal:  Hum Genet       Date:  1994-02       Impact factor: 4.132

Review 6.  Autosomal recessive transmission of hemophilia A due to a von Willebrand factor mutation.

Authors:  R J Wise; B M Ewenstein; J Gorlin; S C Narins; M Jesson; R I Handin
Journal:  Hum Genet       Date:  1993-05       Impact factor: 4.132

7.  Rare and low-frequency variants and their association with plasma levels of fibrinogen, FVII, FVIII, and vWF.

Authors:  Jennifer E Huffman; Paul S de Vries; Alanna C Morrison; Maria Sabater-Lleal; Tim Kacprowski; Paul L Auer; Jennifer A Brody; Daniel I Chasman; Ming-Huei Chen; Xiuqing Guo; Li-An Lin; Riccardo E Marioni; Martina Müller-Nurasyid; Lisa R Yanek; Nathan Pankratz; Megan L Grove; Moniek P M de Maat; Mary Cushman; Kerri L Wiggins; Lihong Qi; Bengt Sennblad; Sarah E Harris; Ozren Polasek; Helene Riess; Fernando Rivadeneira; Lynda M Rose; Anuj Goel; Kent D Taylor; Alexander Teumer; André G Uitterlinden; Dhananjay Vaidya; Jie Yao; Weihong Tang; Daniel Levy; Melanie Waldenberger; Diane M Becker; Aaron R Folsom; Franco Giulianini; Andreas Greinacher; Albert Hofman; Chiang-Ching Huang; Charles Kooperberg; Angela Silveira; John M Starr; Konstantin Strauch; Rona J Strawbridge; Alan F Wright; Barbara McKnight; Oscar H Franco; Neil Zakai; Rasika A Mathias; Bruce M Psaty; Paul M Ridker; Geoffrey H Tofler; Uwe Völker; Hugh Watkins; Myriam Fornage; Anders Hamsten; Ian J Deary; Eric Boerwinkle; Wolfgang Koenig; Jerome I Rotter; Caroline Hayward; Abbas Dehghan; Alex P Reiner; Christopher J O'Donnell; Nicholas L Smith
Journal:  Blood       Date:  2015-06-23       Impact factor: 22.113

8.  Interaction Between the a3 Region of Factor VIII and the TIL'E' Domains of the von Willebrand Factor.

Authors:  Lisbeth Dagil; Kathrin S Troelsen; Gert Bolt; Lars Thim; Bo Wu; Xin Zhao; Edward G D Tuddenham; Thomas E Nielsen; David A Tanner; Johan H Faber; Jens Breinholt; Jakob E Rasmussen; D Flemming Hansen
Journal:  Biophys J       Date:  2019-07-11       Impact factor: 4.033

9.  What a polyclonal antibody sees in von Willebrand factor.

Authors:  Fen-Lai Tan; David Ginsburg
Journal:  Thromb Res       Date:  2007-07-05       Impact factor: 3.944

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.